Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Vinorelbine, also known as Navelbine, is a semi-synthetic vinca alkaloid chemotherapy agent derived from the periwinkle plant *Catharanthus roseus*. It functions primarily as a mitotic inhibitor by binding to tubulin, thereby preventing microtubule polymerization and arresting cell division during the metaphase stage of the cell cycle. This mechanism makes it highly effective against rapidly dividing cancer cells. The molecular formula of Vinorelbine is C46H56N2O9, and its Chemical Abstracts Service (CAS) registry number is 71488-00-3.
Clinically, Vinorelbine is widely utilized in the treatment of non-small cell lung cancer (NSCLC), both as a first-line therapy in combination with platinum-based regimens like cisplatin or carboplatin, and for advanced cases where other treatments have failed. It is also approved for use in breast cancer, particularly for patients who have progressed after anthracycline and taxane therapies. Additionally, it has shown efficacy in various lymphomas and soft tissue sarcomas. Due to its specific pharmacokinetic profile, Vinorelbine offers a distinct advantage over older vinca alkaloids like vincristine, exhibiting less neurotoxicity while maintaining potent antitumor activity.
The drug is typically administered intravenously, requiring careful monitoring due to potential side effects such as myelosuppression, which manifests as neutropenia, fatigue, and constipation. Alopecia and local phlebitis at the injection site are also common concerns. Despite these challenges, Vinorelbine remains a cornerstone in oncology protocols, offering improved quality of life and survival rates for many patients with aggressive malignancies. Its unique structure allows for better penetration into tumor tissues compared to its predecessors, making it a versatile option in modern chemotherapy combinations. Ongoing research continues to explore its potential in novel therapeutic strategies and combination regimens to further enhance clinical outcomes.